Ligand Pharmaceuticals Incorporated (LGND) trades at a trailing P/E of 32.3, forward P/E of 26.9. Trailing earnings yield is 3.09%, forward earnings yield 3.72%. PEG 0.66 (Peter Lynch undervalued ≤1.0). Graham Number is $85.56.
Criteria proven by this page:
Overall SharesGrow Score: 77/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1,293.8 | 12.86 | 5.71 | 19.42 | - |
| 2017 | 229.4 | -0.27 | 6.88 | 20.41 | - |
| 2018 | 22.8 | 0.03 | 5.82 | 12.98 | - |
| 2019 | 3.1 | 0.01 | 2.58 | 16.47 | - |
| 2020 | -539.2 | 5.36 | 2.27 | 9.84 | - |
| 2021 | 45.0 | -0.02 | 3.13 | 10.63 | - |
| 2022 | -33.8 | 0.21 | 1.89 | 5.74 | - |
| 2023 | 23.7 | -0.09 | 1.76 | 9.41 | - |
| 2024 | -486.1 | 4.53 | 2.36 | 11.73 | - |
| 2025 | 29.4 | -0.01 | 3.59 | 13.64 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.08 | $108.97M | $-1.64M | -1.5% |
| 2017 | $0.53 | $141.1M | $12.56M | 8.9% |
| 2018 | $5.96 | $251.45M | $143.32M | 57% |
| 2019 | $31.85 | $120.28M | $629.3M | 523.2% |
| 2020 | $-0.18 | $186.42M | $-2.99M | -1.6% |
| 2021 | $3.31 | $277.13M | $57.14M | 20.6% |
| 2022 | $-0.31 | $196.25M | $-5.22M | -2.7% |
| 2023 | $2.94 | $131.31M | $52.15M | 39.7% |
| 2024 | $-0.22 | $167.13M | $-4.03M | -2.4% |
| 2025 | $6.13 | $268.09M | $124.45M | 46.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $8.63 | $8.40 – $8.77 | $267.08M | $262.09M – $275.89M | 7 |
| 2027 | $9.90 | $9.30 – $10.30 | $317.57M | $306.48M – $341.03M | 6 |
| 2028 | $10.31 | $4.43 – $20.76 | $370.03M | $363.26M – $376.79M | 3 |
| 2029 | $11.25 | $10.58 – $12.11 | $422.42M | $403.1M – $447.27M | 1 |
| 2030 | $14.51 | $13.65 – $15.62 | $506.41M | $483.24M – $536.2M | 1 |
